Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics將參加H.C. Wainwright第二屆年度BioConnect投資者會議
Download as PDF May 13, 2024
以 PDF 格式下載 2024 年 5 月 13 日
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference.
馬薩諸塞州沃爾瑟姆，2024年5月13日（GLOBE NEWSWIRE）——臨床階段免疫療法和靶向腫瘤公司Checkpoint Therapeutics, Inc.（“Checkpt”）（納斯達克股票代碼：CKPT）今天宣佈，總裁兼首席執行官詹姆斯·奧利維羅將參加2024年5月20日星期一在納斯達克舉行的H.C. Wainwright第二屆年度生物連接投資者會議的爐邊談話，美國東部時間下午 12:30Checkpoint還將在會議期間參加面對面的一對一會議。
A webcast of the fireside chat will be available on the News & Events page, located within the Investors section of Checkpoint's website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days after the meeting.
爐邊談話的網絡直播將在Checkpoint網站投資者部分的新聞與活動頁面上播出， https://ir.checkpointtx.com/event-calendar/default.aspx，在會後約30天內舉行。
About Checkpoint Therapeutics
關於檢查點療法
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cSCC. Checkpoint is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib (formerly CK-101), a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.checkpointtx.com.
Checkpoint Therapeutics, Inc. 是一家臨床階段的免疫療法和靶向腫瘤學公司，專注於實體瘤癌患者新療法的收購、開發和商業化。Checkpoint正在評估其主要候選抗體產品cosibelimab，一種潛在的最佳抗PD-L1抗體，該抗體由達納-法伯癌症研究所授權，是特定複發性或轉移性癌症（包括轉移性和局部晚期cSCC）患者的潛在新療法。Checkpoint還在評估其領先的小分子靶向抗癌藥物奧法替尼（前身爲 CK-101），這是一種第三代表皮生長因子受體（“EGFR”）抑制劑，作爲表皮生長因子突變陽性非小細胞肺癌患者的潛在新療法。Checkpoint總部位於馬薩諸塞州沃爾瑟姆，由豐澤生物技術公司（納斯達克股票代碼：FBIO）創立。欲了解更多信息，請訪問 www.checkpointtx.com。
Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
公司聯繫人：
Jaclyn Jaffe
Checkpoint Therapeu
(781) 652-4500
ir@checkpointtx.com
Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com
投資者關係聯繫人：
阿什莉·羅賓遜
LifeSCI Advisors, LLC董事總經理
(617) 430-7577
arr@lifesciadvisors.com
Media Relations Contact:
Katie Kennedy
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com
媒體關係聯繫人：
凱蒂肯尼迪
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com
Source: Checkpoint Therapeutics, Inc
資料來源：檢查點療法公司
Released May 13, 2024
2024 年 5 月 13 日發佈